Pathophysiology and clinical manifestations of the β-thalassemias

Cold Spring Harbor Perspectives in Medicine

Volumn 2, Issue 12, 2012, Pages

  Nienhuis, Arthur W ^a   Nathan, David G ^b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; HEMOGLOBIN ALPHA CHAIN; HEMOGLOBIN BETA CHAIN; HEMOGLOBIN E; HEMOGLOBIN F; HEMOGLOBIN GAMMA CHAIN; HEPCIDIN; IRON; IRON CHELATING AGENT; REACTIVE OXYGEN METABOLITE; TRANSFERRIN; GLOBIN;

ANEMIA; ARTICLE; BETA THALASSEMIA; CELL SURVIVAL; CHELATION THERAPY; DISEASE SEVERITY; ERYTHROPOIESIS; EXTRAMEDULLARY HEMATOPOIESIS; GENE MUTATION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; HEART DISEASE; HEMOGLOBIN SYNTHESIS; HEPATOSPLENOMEGALY; HETEROZYGOTE DETECTION; HUMAN; HUNTINGTON CHOREA; IRON ABSORPTION; IRON CHELATION; IRON OVERLOAD; LIVER CELL CARCINOMA; NONHUMAN; NUTRITIONAL DEFICIENCY; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHENOTYPE; PULMONARY HYPERTENSION; THALASSEMIA INTERMEDIA; THALASSEMIA MAJOR; BIOSYNTHESIS; ENDOCRINE DISEASE; GENETICS; HETEROZYGOTE; HOMOZYGOTE; LIVER DISEASE; METABOLISM; MUTATION; SINGLE NUCLEOTIDE POLYMORPHISM;

ANEMIA; BETA-THALASSEMIA; ENDOCRINE SYSTEM DISEASES; GLOBINS; HEART DISEASES; HEMOGLOBIN E; HETEROZYGOTE; HOMOZYGOTE; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; LIVER DISEASES; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84877309853     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a011726     Document Type: Article

References (105)

1. Anderson LJ, Westwood MA, Holden S, Davis B, Prescott E, Wonke B, Porter JB, Walker JM, Pennell DJ. 2004. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: A prospective study using T2* cardiovascular magnetic resonance. Br J Haematol 127: 348-355.
2. Bank A, Marks PA. 1966. Excess α chain synthesis relative to β chain synthesis in thalassaemia major and minor. Nature 212: 1198-1200.
3. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del VecchioGC, Romeo MA, Forni GL, Gamberini MR, Ghilardi R, et al. 2004. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 89: 1187-1193.
4. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Fomi GL, Gamberini MR, Ghilard R, Piga A, Romeo MA, Zhao H, et al. 2006. Cardiac morbidity and mortality in deferoxamine-or deferiprone-treated patients with thalassemia major. Blood 107: 3733-3737.
5. Borgna-Pignatti C, Marsella M, Zanforrin N. 2010. The natural history of thalassemia intermedia. Ann NY Acad Sci 1202: 214-220.
6. Boyer Sh, Belding TK, Margolet L, Noyes AN. 1975. Fetal hemoglobin restriction to a few erythrocytes (F cells) in normal human adults. Science 188: 361-363.
7. Breuer W, Ermers MJ, Pootrakul P, Abramov A, Hershko C, Cabantichik ZI. 2001. Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy. Blood 197: 792-798.
8. Brittenham GM, Farrell DE, Harris JW, Feldman ES, Danish EH, Muir WA, TrippJH, Bellon EM. 1982. Magnetic-susceptibility measurement of human iron stores. N Engl J Med 307: 1671-1675.
9. Brittenham GM, Cohen AR, McLaren Ce, Martin MB, Griffith PM, Nienhuis AW, Young NS, Allen CJ, Farrell DE, Harris JW. 1993. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol 42: 81-85.
10. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, Allen CJ, Farrell DE, Harris JW. 1994. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1331: 567-573.
11. Brittenham GM, Nathan DG, Olivieri NF, Pippard MJ, Weatherall DJ. 2003. Deferiprone versus desferrioxamine in thalassaemia and T2* validation and utility. Lancet 361: 183.
12. Cao A, Galanello R. 2010. β-Thalassemia. Genet Med 12: 61-76.
13. Cao A, Galanello R, Rosatelli MC. 1994. Genotype-phenotype correlations in β-thalassemias. Blood Rev 8: 1-12.
14. Cappellini MD, Motta I, Musallam KM, Taher AT. 2010. Redefining thalassemia as a hypercoagulable state. Ann NY Acad Sci 1202: 231-236.
15. Carpenter JP, He T, Kirk P, Roughton M, Anderson LJ, de Noronha SV, SheppardMN, Porter JB, Walker JM, Wood JC, et al. 2011. On T2* magnetic resonance and cardiac iron. Circulation 123: 1519-1528.
16. Chatterjee R, Bajoria R. 2010. Critical appraisal of growth retardation and pubertal disturbances in thalassemia. Ann NY Acad Sci 1202: 100-114.
17. Engle MA. 1964. Cardiac involvement in Cooley's anemia. Ann NY Acad Sci 119: 694-702.
18. Esposito BP, Breuer W, Sirankapracha P, Pootrakul P, Hershko C, Cabantchik ZI. 2003. Labile plasma iron in iron overload: Redox activity and susceptibility to chelation. Blood 102: 2670-2677.
19. Evans RW, Rafique R, Zarea A, Rapisarda C, Cammack R, Evans PJ, Porter JB, Hider RC. 2008. Nature of non-transferrin-bound iron: Studies on iron citrate complexes and thalassemic sera. J Biol Inorg Chem 13: 57-74.
20. Farmaki T, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V. 2010. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol 148: 466-475.
21. Farrell JJ, Sherva RM, Chen Z, Luo H, Chu BF, Ha SY, Li CK, Lee ACW, Li RCH, LiCK, et al. 2011. A 3-bp deletion in the HBSIl-MYB intergenic region of chromosome 6q23 is associated with HbF expression. Blood 117: 4935-4945.
22. Fucharoen S, Weatherall DJ. 2012. The hemoglobin E thalassemias. Cold Spring Harb Perspect Med 2: a011734.
23. Fung EB. 2010. Nutritional deficiencies in patients with thalassemia. Ann NY Acad Sci 1202: 188-196.
24. Gabuzda TG, Nathan DG, Gardner FH. 1962. Comparative metabolism of haemoglobins A and F in thalassaemia. Nature 196: 781-782.
25. 0 thalassemia by genetic modifiers. Blood 114: 3935-3937.
26. Galarneau G, Palmer CD, Sankaran VG, Orkin SH, Hirschhorn JN, Lettre G. 2010. Fine-mapping at three loci known to affect fetal hemoglobin levels explains additional genetic variation. Nat Genet 42: 1049-1051.
27. Gandon Y, Olivie D, Guyader D, Aube C, Oberti F, Sebille V, Deugnier Y. 2004. Non-invasive assessment of hepatic iron stores by MRI. Lancet 363: 357-362.
28. Ganz T, Nemeth E. 2011. Hepcidin and disorders of iron metabolism. Annu Rev Med 62: 347-360.
29. Ganz T, Nemeth E. 2012. Iron metabolism: Interactions with normal and disordered erythropoiesis. Cold Spring Harb Perspect Med 2: a011668.
30. Garner C, Tatu T, Reittie JE, Littlewood T, Darley J, Cervino S, Farrall M, Kelly P, Spector TD, Thein SL. 2000. Genetic influences on F cells and other hematologic variables: A twin heritability study. Blood 95: 342-346.
31. Garner C, Dew TK, Sherwood R, Rees D, Thein SL. 2003. Heterocellular hereditary persistence of fetal haemoglobin affects the haematological parameters of β-thalassemia trail. Br J Haematol 123: 353-358.
32. Ginzburg Y, Rivella S. 2011. β-Thalassemia: A model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism. Blood 118: 4321-4330.
33. Glickstein H, Ben El R, Link G, Breuer W, Konijn AM, Hershko C, Nick H, Cabantchik ZI. 2006. Action of chelators in iron-loaded cardiac cells: Accessibility to intracellular labile iron and functional consequences. Blood 108: 3195-3203.
34. Hershko C. 2010. Pathogenesis and management of iron toxicity in thalassemia. Ann NY Acad Sci 1202: 1-9.
35. Hershko C, Graham G, Bates GW, Rachmilewitz EA. 1978. Non-specific serum iron in thalassaemia: An abnormal serum iron fraction of potential toxicity. Br J Haematol 40: 255-263.
36. Hershko C, Link G, Konijn AM, Cabantchik ZI. 2005. Objectives and mechanism of iron chelation therapy. Ann NY Acad Sci 1054: 124-135.
37. Italia KY, Jijina FJ, Merchant R, Panjwani S, Nadkarni AH, Sawant PM, Nair SB, Ghosh K, Colah RB. 2009. Response to hydroxyurea in β thalassemia major and intermedia: Experience in western India. Clin Chim Acta 407: 10-15.
38. Kan YW, Nathan DG. 1970. Mild thalassemia: The result of interactions of α and β thalassemia genes. J Clin Invest 49: 635-642.
39. Karimi M, Haghpanah S, Farhadi A, Yavarian M. 2011. Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: A 13-year experience in Iran. Int J Hematol 95: 51-56.
40. Khandros E, Weiss MJ. 2010. Protein quality control during erythropoiesis and hemoglobin synthesis. Hematol Oncol Clin N Am 24: 1071-1088.
41. Khandros E, Thom CS, D'Souza J, Weiss MJ. 2011. Integrated protein quality control pathways degrade free α globin in β-thalassemia. Blood 119: 5265-5275.
42. Kim D, Jensen JH, Wu EX, Feng L, Au WY, Cheung JS, Ha SY, Sheth SS, Brittenham GM. 2011. Rapid monitoring of iron-chelating therapy in thalassemia major by a new carciovascular MR measure: The reduced transverse relaxation rate. NRM Biomed 24: 771-777.
43. Kong Y, Zhou S, Kihm A, Katein AM, Yu X, Gell DA, Mackay JP, Adachi K, Foster-Brown L, Louden CS, et al. 2004. Loss of α-hemoglobin-stabilizing protein impairs erythropoiesis and exacerbates β-thalassemia. J Clin Invest 114: 1457-1466.
44. Labie D, Pagnier J, Lapoumeroulie C, Rauabhi F, Dunda-Belkhodja O, ChardinP, Beldjord C, Wajcman H, Fabry ME, Nagel RL. 1985. Common haplotype dependency of high G γ-globin gene expression and high HbF levels in β-thalassemia and sickle cell anemia patients. Proc Natl Acad Sci 82: 2111-2114.
45. Lai MI, Jiang J, Silver N, Best S, Menzel S, Mijovic A, Colella S, Ragoussi J, Garncer C, Weiss MJ, et al. 2006. α-haemoglobin stabilizing protein is a quantitative trait gene that modifies the phenotype of β-thalassaemia. Br J Haematol 133: 675-682.
46. Leung TF, Chu Y, Lee Y, Cheng FW, Leung WK, Shing MM, Li CK. 2009. Long-term effects of pamidronate in thalassemic patients with severe bone mineral density deficits. Hemoglobin 33: 361-369.
47. Liuzzi JP, Avdemir F, Nam H, Knutson MD, Cousins RJ. 2006. Zip 14 (Slc39a14) mediates non-transferrin-bound iron uptake into cells. Proc Natl Acad Sci 103: 13612-13617.
48. Mancuso A. 2010. Hepatocellular carcinoma in thalassemia: A critical review. World J Hepatol 2: 171-174.
49. Mathias LA, Fisher TC, Zeng L, Meiselman HJ, Weinberg KI, Hiti AL, Malik P. 2000. Ineffective erythropoiesis in β-thalassemia major is due to apoptosis at the polychromatophilic normoblast stage. Exp Hematol 28: 1343-1353.
50. Morris CR, Vichinsky EP. 2010. Pulmonary hypertension in thalassemia. Ann NY Acad Sci 1202: 205-213.
51. Morris CR, Kim HY, Trachtenberg F, Wood J, Quinn CT, Sweeters N, Kwiatkowski JL, Thompson AA, Giardina PJ, Boudreaux J, et al. 2011. Risk factors and mortality associated with an elevated tricuspid regurgitant jet velocity measured by Doppler-echocardiography in thalassemia: A thalassemia clinical research network report. Blood 18: 3794-3802.
52. Musallam KM, Sankaran VG, Cappellini MD, Duca L, Nathan DG, Taher AT. 2012. Fetal hemoglobin levels and morbidity in untransfused patients with β-thalassemia intermedia. Blood 119: 364-367.
53. Nathan DG, Gunn RB. 1966. Thalassemia: The consequences of unbalanced hemoglobin synthesis. Am J Med 4: 815-830.
54. Nathan DG, Stossel TB, Gunn RB, Zarkowsky HS, Laforet MT. 1969. Influence of hemoglobin precipitation on erythrocyte metabolism in α and β thalassemia. J Clin Invest 48: 33-41.
55. Nemeth E. 2010. Hepcidin in β-thalassemia. Ann NY Acad Sci 1202: 31-35.
56. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J. 2004. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306: 2051-2053.
57. Noetzli LJ, Mittelman SD, Watanabe RM, Coates TD, Wood JC. 2011. Pancreatic iron and glucose dysregulation in thalassemia major. Am J Hematol doi: 10. 1002/ajh. 22223.
58. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, Martin M, Koren G, Cohen AR. 1994. Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med 331: 574-578.
59. Olivieri NF, Muraca GM, O'Donnell A, Premawardhena A, Fisher C, WeatherallDJ. 2008. Studies in haemoglobin E β-thalassaemia. Br J Haematol 141: 388-397.
60. Olivieri NF, Pakbaz Z, Vichinsky E. 2010a. HbE/β-thalassemia: Basis of marked clinical diversity. Hematol Oncol Clin North Am 24: 1055-1070.
61. Olivieri NF, Thayalsuthan V, O'Donnell A, Premawardhena A, Rigobon C, Muraca G, Fisher C, Weatherall DJ. 2010b. Emerging insights in the management of hemoglobin E β thalassemia. Ann NY Acad Sci 1202: 155-157.
62. Orkin SH, Kazzazian HH Jr., Antonarakis SE, Oster H, Goff SC, Sexton JP. 1982. Abnormal RNA processing due to the exon mutation of β E-globin gene. Nature 300: 768-769.
63. 2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat Med 9: 1187-1194.
64. 2+channels in iron transport and iron-overload cardiomyopathy. J Mol Med (Berl)84: 349-364.
65. Pennell DJ, Porter JB, Cappellini MD, El-Beshlawy A, Chan LL, Aydinok Y, ElalfyMS, Sutcharitchan P, Li CK, Ibrahim H, et al. 2010. Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia. Blood 115: 2364-2371.
66. Pennell DJ, Porter JB, Cappellini MD, Chan LL, El-Beshlawy A, Aydinok Y, Ibrahim H, Li CK, Viprakasit V, Elalfy MS, et al. 2011. Continued improvement in myocardial T2* over two years of deferasirox therapy in thalassemia major patients with cardiac iron overload. Haematologica 96: 48-54.
67. Pippard MJ, Callender ST, Weatherall DJ. 1978. Intensive iron-chelation therapy with desferrioxamine in iron loading patients. Clin Sci Mol Med 54: 99-106.
68. 0 thalassemia in Sardinia. Science 223: 929-930.
69. Pootrakul P, Breuer W, Sametband M, Sirankapracha P, Hershko C, CabantchikZI. 2004. Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded β-thalassemia/HbE patients treated with an oral chelator. Blood 104: 1504-1510.
70. Porter JB, Abeysinghe RD, Marshall L, Hider RC, Singh S. 1996. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy. Blood 88: 705-713.
71. Premawardhena A, Fisher CA, Olivieri NF, de Silva S, Sloane-Stanley J, WoodWG, Weatherall DJ. 2005. A novel molecular basis for β thalassemia intermedia poses new questions about its pathophysiology. Blood 106: 3251-3255.
72. Premawardhena A, Arambepola M, Katugaha N, Weatherall DJ. 2008. Is the β thalassaemia trait of clinical importance? Br J Haematol 141: 407-410.
73. Preza GC, Ruchala P, Pinon R, Ramos E, Qiao B, Perallta MA, Sharma S, WaringG, Ganz T, Nameth E. 2011. Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for treatment of iron overload. J Clin Invest 121: 4880-4888.
74. Propper RD, Shurin SB, Nathan DG. 1976. Reassessment of the use of desferrioxamine B in iron overload. N Engl J Med 294: 1421-1423.
75. Propper RD, Cooper B, Rufo RR, Nienhuis AW, Anderson WF, Burn HF, Rosenthal A, Nathan DG. 1977. Continuous subcutaneous administration of deferoxamine in patients with iron overload. N Engl J Med 25: 418-423.
76. Rachmilewitz EA, Giardina PJ. 2011. How I treat thalassemia. Blood 118: 3479-3488.
77. Rund D, Rachmilewitz E. 2005. β-Thalassemia. N Engl J Med 353: 1135-1146.
78. Sankaran VG, Nathan DG. 2010. Thalassemia: An overview of 50 years of clinical research. Hematol Oncol N Am 24: 1005-1020.
79. Sankaran VG, Orkin SH. 2013. The switch from fetal to adult hemoglobin. Cold Spring Harb Perspect Med doi: 10. 1101/cshperspect. a011643.
80. Sankaran VG, Xu J, Ragoczy T, Ippolito GC, Walkley CR, Maika SD, Fujiwara Y, Ito M, Groudine M, Bender MA, et al. 2009. Developmental and species-divergent globin switching are driven by BCL11A. Nature 460: 1093-1097.
81. Sankaran VG, Xu J, Byron R, Greisman HA, Fisher C, Weatherall DJ, Sabath DE, Groudine M, Orkin SH, Premawardhena A, et al. 2011. A functional element necessary for fetal hemoglobin silencing. N Engl J Med 365: 807-814.
82. St Pierre TG, Clark PR, Chua-Anusom W, Fleming AJ, Jeffrey GP, Olynyk JK, Pootrakul P, Robins E, Lindeman R. 2005. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 105: 855-861.
83. Taher AT, Musallam KM, Cappellini MD, Weatherall DJ. 2011. Optimal management of β thalassaemia intermedia. Br J Haematol 152: 512-523.
84. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, RoughtonM, Assomull R, Nair SV, Walker JM, et al. 2007. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 115: 1876-1884.
85. Tanno T, Bhanu NV, Oneal PA, Goh SH, Staker P, Lee YT, Moroney JW, Reed CH, Luban NL, Wang RH, et al. 2007. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 13: 1096-1101.
86. Tanno T, Porayette P, Sripichai O, Noh SJ, Byrnes C, Bhupatiraju A, Lee YT, Goodnough JB, Harandi O, Ganz T, et al. 2009. Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood 114: 181-186.
87. Tassiopoulos S, Deftereos S, Konstantopoulos K, Farmakis D, Tsironi M, Kyriakdis M, Aessopos A. 2005. Does heterozygous β-thalassemia confer a protection against coronary artery disease? Ann NY Acad Sci 1054: 467-470.
88. Terpos E, Voskaridou E. 2010. Treatment options for thalassemia patients with osteoporosis. Ann NY Acad Sci 1202: 237-243.
89. Thein SL. 1999. Is it dominantly inherited β thalassemia or just a β-chain variant that is highly unstable? Br J Haematol 107: 12-21.
90. Thein SL. 2013. Molecular basis of β thalassemia. Cold Spring Harb Perspect Med doi: 10. 1101/cshperspect. a011700.
91. Uda M, Galanello R, Sanna S, Lettre G, Sankaran VG, Chen W, Usala G, BusoneroF, Maschio A, Albai G, et al. 2008. Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of phenotype of β-thalassemia. Proc Natl Acad Sci 105: 1620-1625.
92. Wainscoat JS, Kanavakis E, Wood WG, Letsky EA, Huehns ER, Marsh GW, HiggsDR, Clegg JB, Weatherall DJ. 1983. Thalassaemia intermedia in Cyprus: The interaction of α and β thalassaemia. Br J Haematol 53: 411-416.
93. Weatherall DJ. 2001. Phenotype-genotype relationships in monogenic disease: Lessons from the thalassemias. Nat Rev Genet 2: 245-255.
94. Weatherall DJ, Clegg JB. 2001. The thalassemia syndromes, 4th ed. Blackwell Science, Oxford.
95. Weatherall DJ, Clegg JB, Naughton MA. 1965. Globin synthesis in thalassemia: An in vitro study. Nature 208: 1061-1065.
96. Weiss MJ, dos Santos CO. 2009. Chaperoning erythropoiesis. Blood 113: 2136-2144.
97. White JM, Richards R, Byrne M, Buchanan T, White YS, Jelenski G. 1985. Thalassemia trait and pregnancy. J Clin Pathol 38: 810-817.
98. + cells after lentiviral vector-mediated gene transfer. Blood 117: 2817-2826.
99. Wilber A, Nienhuis AW, Persons DA. 2011b. Transcriptional regulation of fetal to adult hemoglobin switching: New therapeutic opportunities. Blood 117: 3945-3953.
100. Wolfe L, Olivieri N, Sallan D, Colan S, Rose V, Propper R, Freedman MH, NathanDG. 1985. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. N Engl J Med 312: 1600-1603.
101. Wood JC. 2011. Impact of iron assessment by MRI. Hematology Am Soc Hematol Educ Program 2011: 443-450.
102. Wu EX, Kim D, Tosti CL, Tang H, Jensen JH, Cheung JS, Feng L, Au WY, Ha SY, Sheth SS, et al. 2010. Magnetic resonance assessment of iron overload by separate measurement of tissue ferritin and hemosiderin iron. Ann NY Acad Sci 1202: 115-122.
103. Xu J, Peng C, Sankaran VG, Shao Z, Esrick EB, Chong BG, Ippolito GC, FujiwaraY, Ebert BL, Tucker PW, et al. 2011. Correction of sickle cell disease in adult mice by interference with fetal hemoglobin silencing. Science 334: 993-996.
104. Yu X, Kong Y, Dore LC, Abdulmalik O, Katein AM, Zhou S, Choi JK, Gell D, Mackay JP, Gow AJ, et al. 2007. An erythroid chaperone that facilitates folding of α-globin subunits for hemoglobin synthesis. J Clin Invest 117: 1856-1865.
105. Yu X, Mollan TL, Butler A, Gow AJ, Olson JS, Weiss MJ. 2009. Analysis of human α globin gene mutations that impair binding to the α hemoglobin stabilizing protein. Blood 113: 5961-5969.